Monovo (Mometasone Furoate)

Mometasone furoate, the active ingredient in Monovo, is a corticosteroid presented as a topical preparation for topical use. It is employed to reduce inflammation and relieve symptoms in various skin disorders such as psoriasis, atopic dermatitis, eczema and seborrheic dermatitis.

GNH USA supplies Monovo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Mometasone furoate is a topical corticosteroid used to manage inflammatory skin conditions.

- Psoriasis: reduces scaling, redness and itching associated with plaque lesions. - Atopic dermatitis: alleviates inflammation and pruritus in eczematous patches. - Eczema: diminishes skin irritation and promotes healing of affected areas. - Seborrheic dermatitis: controls flaking and erythema on scalp and facial skin.

Topical application of mometasone furoate may be associated with local and systemic adverse reactions.

Common Side Effects: - Burning or stinging sensation at the application site. - Dryness or peeling of the skin. - Itching or mild irritation. - Redness or erythema.

Serious or Rare Side Effects: - Skin atrophy or thinning with prolonged use. - Telangiectasia (visible small blood vessels). - Secondary bacterial, fungal or viral skin infections. - Hypersensitivity reactions such as contact dermatitis.

When using mometasone furoate, certain precautions should be observed to minimize risks. - Application area: limit to affected skin and avoid large surface areas. - Duration: use for the shortest period necessary; avoid continuous use beyond recommended time. - Occlusion: do not cover treated skin with airtight dressings unless directed by a clinician. - Age restrictions: avoid use in children under two years unless specifically prescribed. - Systemic absorption: monitor for signs of adrenal suppression with extensive or prolonged therapy. - Store below 25°C: keep in the original container, protect from moisture and light.

Mometasone furoate can interact with other topical or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors applied concurrently may increase systemic exposure. - Concurrent use of other potent topical corticosteroids can amplify local side effects. - Systemic immunosuppressants may enhance risk of infection when combined.

Moderate Interactions (Monitor Closely): - Antifungal or antibacterial creams may alter skin barrier and affect drug absorption. - Phototherapy may increase skin sensitivity when used with topical steroids. - Herbal skin products containing irritants could exacerbate local irritation.